Feb 12, 2014
|
MacroGenics Announces Pricing of Public Offering of Common Stock
|
|
Feb 10, 2014
|
MacroGenics Announces Proposed Public Offering of Common Stock
|
|
Feb 05, 2014
|
MacroGenics Achieves Milestone as Servier Exercises Option to Develop and Commercialize DART-Based Candidate, MGD006
|
|
Dec 11, 2013
|
MacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer
|
|
Dec 09, 2013
|
MacroGenics Announces Presentation of Pre-Clinical Data on DART(R) Molecule Targeting CD123-Positive Leukemic Stem Cells at 55th Annual Meeting of the American Society of Hematology
|
|
Nov 12, 2013
|
MacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results
|
|
Nov 11, 2013
|
MacroGenics to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th ASH Annual Meeting
|
|
Nov 11, 2013
|
MacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate
|
|
Nov 05, 2013
|
MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call
|
|
Oct 16, 2013
|
MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option
|
|
Oct 09, 2013
|
MacroGenics Announces Pricing of Initial Public Offering
|
|
Sep 19, 2013
|
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman
|
|
Aug 20, 2013
|
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
|
|
Aug 12, 2013
|
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
|
|
Jun 03, 2013
|
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer
|
|
May 21, 2013
|
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
|
|
Jan 07, 2013
|
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products
|
|
Sep 20, 2012
|
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products
|
|
Sep 05, 2012
|
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases
|
|
Dec 20, 2011
|
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim
|
|
Dec 01, 2011
|
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
|
|
Jun 28, 2011
|
The Lancet Publishes Data from Protégé, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
|
|
Jun 23, 2011
|
MacroGenics Announces Presentation of Protégé Phase 3 Clinical Data at ADA in San Diego on June 28
|
|
Apr 28, 2011
|
Data Published in Blood Demonstrate Potent Activity of MacroGenics' Proprietary DART™ Technology
|
|
Jan 06, 2011
|
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-Expressing Solid Tumors
|
|